The Experts below are selected from a list of 519 Experts worldwide ranked by ideXlab platform
Bhagwant Rai Mittal - One of the best experts on this subject based on the ideXlab platform.
-
comparative performance of 99mtc trodat 1 spect ct and 18f fdopa pet ct imaging in patients with Parkinson s disease Parkinson Plus Syndrome and essential tremor
Clinical Nuclear Medicine, 2021Co-Authors: Apurva Sood, Ritu Shree, Manish Modi, Jaya Shukla, Rakhee Vatsa, Bhagwant Rai MittalAbstract:PURPOSE The aim of this study was to assess the utility of presynaptic dopaminergic imaging using 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT and compare their performance in Parkinson's disease (PD), Parkinson-Plus Syndrome (PPS), and essential tremor (ET). PATIENTS AND METHODS A total of 103 patients (PD = 48, PPS = 19, and ET = 36) were enrolled prospectively. Hoehn and Yahr (HY PET, P = 0.61). Substantial agreement (weighted κ = 0.659) was found between 99mTc-TRODAT-1 and 18F-FDOPA for the detection of presynaptic dopaminergic dysfunction. Specific uptake ratio of striatum correlation between SPECT and PET was statistically significant (r = 0.67; P < 0.01). A negative but nonsignificant correlation was found between the SURs and H&Y staging/MDS-UPDRS. CONCLUSIONS Both 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT showed substantial agreement and proved to be potential imaging biomarker for the detection of dopaminergic dysfunction, thus assisting in differentiating early PD/PD and PPS from ET cases.
Apurva Sood - One of the best experts on this subject based on the ideXlab platform.
-
comparative performance of 99mtc trodat 1 spect ct and 18f fdopa pet ct imaging in patients with Parkinson s disease Parkinson Plus Syndrome and essential tremor
Clinical Nuclear Medicine, 2021Co-Authors: Apurva Sood, Ritu Shree, Manish Modi, Jaya Shukla, Rakhee Vatsa, Bhagwant Rai MittalAbstract:PURPOSE The aim of this study was to assess the utility of presynaptic dopaminergic imaging using 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT and compare their performance in Parkinson's disease (PD), Parkinson-Plus Syndrome (PPS), and essential tremor (ET). PATIENTS AND METHODS A total of 103 patients (PD = 48, PPS = 19, and ET = 36) were enrolled prospectively. Hoehn and Yahr (HY PET, P = 0.61). Substantial agreement (weighted κ = 0.659) was found between 99mTc-TRODAT-1 and 18F-FDOPA for the detection of presynaptic dopaminergic dysfunction. Specific uptake ratio of striatum correlation between SPECT and PET was statistically significant (r = 0.67; P < 0.01). A negative but nonsignificant correlation was found between the SURs and H&Y staging/MDS-UPDRS. CONCLUSIONS Both 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT showed substantial agreement and proved to be potential imaging biomarker for the detection of dopaminergic dysfunction, thus assisting in differentiating early PD/PD and PPS from ET cases.
-
to evaluate the role of 99m tc trodat 1 spect ct and 18 f fdopa pet ct and their comparative performance in Parkinson disease pd Parkinson Plus Syndrome pps and essential tremor et
2018Co-Authors: Apurva Sood, Ritu Shree, Manish Modi, Bhagwant Mittal, Jaya Shukla, Rakhee VatsaAbstract:Poster: "EANM 18 / EP-0256 / To evaluate the role of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT and their comparative performance in Parkinson Disease (PD), Parkinson Plus Syndrome (PPS) and Essential Tremor (ET)." by: "A. Sood, B. R. Mittal, J. Shukla, M. Modi, R. Shree, R. Vatsa; Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA"
Rakhee Vatsa - One of the best experts on this subject based on the ideXlab platform.
-
comparative performance of 99mtc trodat 1 spect ct and 18f fdopa pet ct imaging in patients with Parkinson s disease Parkinson Plus Syndrome and essential tremor
Clinical Nuclear Medicine, 2021Co-Authors: Apurva Sood, Ritu Shree, Manish Modi, Jaya Shukla, Rakhee Vatsa, Bhagwant Rai MittalAbstract:PURPOSE The aim of this study was to assess the utility of presynaptic dopaminergic imaging using 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT and compare their performance in Parkinson's disease (PD), Parkinson-Plus Syndrome (PPS), and essential tremor (ET). PATIENTS AND METHODS A total of 103 patients (PD = 48, PPS = 19, and ET = 36) were enrolled prospectively. Hoehn and Yahr (HY PET, P = 0.61). Substantial agreement (weighted κ = 0.659) was found between 99mTc-TRODAT-1 and 18F-FDOPA for the detection of presynaptic dopaminergic dysfunction. Specific uptake ratio of striatum correlation between SPECT and PET was statistically significant (r = 0.67; P < 0.01). A negative but nonsignificant correlation was found between the SURs and H&Y staging/MDS-UPDRS. CONCLUSIONS Both 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT showed substantial agreement and proved to be potential imaging biomarker for the detection of dopaminergic dysfunction, thus assisting in differentiating early PD/PD and PPS from ET cases.
-
to evaluate the role of 99m tc trodat 1 spect ct and 18 f fdopa pet ct and their comparative performance in Parkinson disease pd Parkinson Plus Syndrome pps and essential tremor et
2018Co-Authors: Apurva Sood, Ritu Shree, Manish Modi, Bhagwant Mittal, Jaya Shukla, Rakhee VatsaAbstract:Poster: "EANM 18 / EP-0256 / To evaluate the role of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT and their comparative performance in Parkinson Disease (PD), Parkinson Plus Syndrome (PPS) and Essential Tremor (ET)." by: "A. Sood, B. R. Mittal, J. Shukla, M. Modi, R. Shree, R. Vatsa; Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA"
Manish Modi - One of the best experts on this subject based on the ideXlab platform.
-
comparative performance of 99mtc trodat 1 spect ct and 18f fdopa pet ct imaging in patients with Parkinson s disease Parkinson Plus Syndrome and essential tremor
Clinical Nuclear Medicine, 2021Co-Authors: Apurva Sood, Ritu Shree, Manish Modi, Jaya Shukla, Rakhee Vatsa, Bhagwant Rai MittalAbstract:PURPOSE The aim of this study was to assess the utility of presynaptic dopaminergic imaging using 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT and compare their performance in Parkinson's disease (PD), Parkinson-Plus Syndrome (PPS), and essential tremor (ET). PATIENTS AND METHODS A total of 103 patients (PD = 48, PPS = 19, and ET = 36) were enrolled prospectively. Hoehn and Yahr (HY PET, P = 0.61). Substantial agreement (weighted κ = 0.659) was found between 99mTc-TRODAT-1 and 18F-FDOPA for the detection of presynaptic dopaminergic dysfunction. Specific uptake ratio of striatum correlation between SPECT and PET was statistically significant (r = 0.67; P < 0.01). A negative but nonsignificant correlation was found between the SURs and H&Y staging/MDS-UPDRS. CONCLUSIONS Both 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT showed substantial agreement and proved to be potential imaging biomarker for the detection of dopaminergic dysfunction, thus assisting in differentiating early PD/PD and PPS from ET cases.
-
SERUM IGF-1& URIC ACID IN PATIENTS WITH ParkinsonS DISEASE AND Parkinson Plus Syndrome.
2019Co-Authors: Missamma Mulagala, Ritu Shree, Gunjan Goyal, Manoj K Goyal, Sahil Mehta, Manish Modi, B R Mittal, Bikash Medhi.Abstract:Background:Development of biomarkers in Parkinson?s disease (PD) and Parkinson Plus Syndrome (PPS) is still at an elementary stage. Recent studies have yielded conflicting results on the role of insulin like growth factor (IGF-1) & uric acid as biomarkers in PD. We evaluated the role of serum IGF-1 and uric acid as diagnostic and prognostic markers in PD. Objectives: 1. To evaluate the role of serum IGF-1 & uric acid as biomarkers for differentiating PD from Parkinson Plus Syndrome and healthy controls. 2. To study the correlation of levels of serum IGF-1& uric acid with duration and severity of illness in PD. Methods:Current study included 99 patients with Parkinsonism and 68 healthy volunteers. Patients were diagnosed as PD, multisystem atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal ganglionic degeneration (CBGD) as per standard criteria. Written informed consent was obtained from all patients included in the study. All patients underwent complete neurological examination, MMSE (Mini Mental State Examination), UPDRS (Unified Parkinson Disease Rating Scale) and MRI brain. Serum IGF-1 was measured by DRG IGF-1 600 ELISA kit (Catalogue No: 18K116: DRG Instruments Gm BH, Germany). Serum uric acid was measured by INFINITE Uric acid assay kit (Accurex Biomedical PVT.LTD., Mumbai, INDIA). Results:Serum IGF-1 levels were significantly elevated (p
-
to evaluate the role of 99m tc trodat 1 spect ct and 18 f fdopa pet ct and their comparative performance in Parkinson disease pd Parkinson Plus Syndrome pps and essential tremor et
2018Co-Authors: Apurva Sood, Ritu Shree, Manish Modi, Bhagwant Mittal, Jaya Shukla, Rakhee VatsaAbstract:Poster: "EANM 18 / EP-0256 / To evaluate the role of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT and their comparative performance in Parkinson Disease (PD), Parkinson Plus Syndrome (PPS) and Essential Tremor (ET)." by: "A. Sood, B. R. Mittal, J. Shukla, M. Modi, R. Shree, R. Vatsa; Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA"
Ritu Shree - One of the best experts on this subject based on the ideXlab platform.
-
comparative performance of 99mtc trodat 1 spect ct and 18f fdopa pet ct imaging in patients with Parkinson s disease Parkinson Plus Syndrome and essential tremor
Clinical Nuclear Medicine, 2021Co-Authors: Apurva Sood, Ritu Shree, Manish Modi, Jaya Shukla, Rakhee Vatsa, Bhagwant Rai MittalAbstract:PURPOSE The aim of this study was to assess the utility of presynaptic dopaminergic imaging using 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT and compare their performance in Parkinson's disease (PD), Parkinson-Plus Syndrome (PPS), and essential tremor (ET). PATIENTS AND METHODS A total of 103 patients (PD = 48, PPS = 19, and ET = 36) were enrolled prospectively. Hoehn and Yahr (HY PET, P = 0.61). Substantial agreement (weighted κ = 0.659) was found between 99mTc-TRODAT-1 and 18F-FDOPA for the detection of presynaptic dopaminergic dysfunction. Specific uptake ratio of striatum correlation between SPECT and PET was statistically significant (r = 0.67; P < 0.01). A negative but nonsignificant correlation was found between the SURs and H&Y staging/MDS-UPDRS. CONCLUSIONS Both 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT showed substantial agreement and proved to be potential imaging biomarker for the detection of dopaminergic dysfunction, thus assisting in differentiating early PD/PD and PPS from ET cases.
-
SERUM IGF-1& URIC ACID IN PATIENTS WITH ParkinsonS DISEASE AND Parkinson Plus Syndrome.
2019Co-Authors: Missamma Mulagala, Ritu Shree, Gunjan Goyal, Manoj K Goyal, Sahil Mehta, Manish Modi, B R Mittal, Bikash Medhi.Abstract:Background:Development of biomarkers in Parkinson?s disease (PD) and Parkinson Plus Syndrome (PPS) is still at an elementary stage. Recent studies have yielded conflicting results on the role of insulin like growth factor (IGF-1) & uric acid as biomarkers in PD. We evaluated the role of serum IGF-1 and uric acid as diagnostic and prognostic markers in PD. Objectives: 1. To evaluate the role of serum IGF-1 & uric acid as biomarkers for differentiating PD from Parkinson Plus Syndrome and healthy controls. 2. To study the correlation of levels of serum IGF-1& uric acid with duration and severity of illness in PD. Methods:Current study included 99 patients with Parkinsonism and 68 healthy volunteers. Patients were diagnosed as PD, multisystem atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal ganglionic degeneration (CBGD) as per standard criteria. Written informed consent was obtained from all patients included in the study. All patients underwent complete neurological examination, MMSE (Mini Mental State Examination), UPDRS (Unified Parkinson Disease Rating Scale) and MRI brain. Serum IGF-1 was measured by DRG IGF-1 600 ELISA kit (Catalogue No: 18K116: DRG Instruments Gm BH, Germany). Serum uric acid was measured by INFINITE Uric acid assay kit (Accurex Biomedical PVT.LTD., Mumbai, INDIA). Results:Serum IGF-1 levels were significantly elevated (p
-
to evaluate the role of 99m tc trodat 1 spect ct and 18 f fdopa pet ct and their comparative performance in Parkinson disease pd Parkinson Plus Syndrome pps and essential tremor et
2018Co-Authors: Apurva Sood, Ritu Shree, Manish Modi, Bhagwant Mittal, Jaya Shukla, Rakhee VatsaAbstract:Poster: "EANM 18 / EP-0256 / To evaluate the role of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT and their comparative performance in Parkinson Disease (PD), Parkinson Plus Syndrome (PPS) and Essential Tremor (ET)." by: "A. Sood, B. R. Mittal, J. Shukla, M. Modi, R. Shree, R. Vatsa; Post Graduate Institute of Medical Education and Research, Chandigarh, INDIA"